World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Cited by in CrossRef

For:	Kritzinger J, Candel I, Kotrri G, Nadeem H, Afif W, Bitton A, Wild G, Bessissow T, Lakatos PL. Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. World J Gastroenterol 2025; 31(48): 114355 [PMID: 41480329 DOI: 10.3748/wjg.v31.i48.114355]
URL:	https://www.wjgnet.com/1007-9327/full/v31/i48/114355.htm

(48) (56) (0) (0) (0) (1) (1475) (6)

Number	Citing Articles
1	Esteban Fuentes-Valenzuela, Irene Chivato Martín-Falquina , José Antonio Olmos Jerez , María del Carmen López-Martín , Almudena Calvache , Marina Gil Santana , Carlos Castaño Milla , Alicia Bejerano Domínguez. Short and medium-term outcomes of ustekinumab biosimilar in patients with Crohn�s disease in na�ve patients and after switching from originator. Revista Española de Enfermedades Digestivas 2026; doi: 10.17235/reed.2026.11878/2026
2	Qin-Jian Wang, Zheng Zhu, Guang-Rong Lu. Letter to the Editor: Missing mechanistic data and small inflammatory bowel disease cohorts: Key barriers in ustekinumab switching. World Journal of Gastroenterology 2026; 32(19): 117160 doi: 10.3748/wjg.v32.i19.117160 Abstract(132) \| Core Tip(97) \| Full Article(HTML)(443) \| Full Article (PDF)-356K(239) \| Full Article with Cover (PDF)-835K(59) \| Full Article (XML)-55K(35) \| Audio-798K(7) \| Peer-Review Report-242K(45) \| Answering Reviewers-82K(42) \| Times Cited (0) \| Total Visits (776) \| Open
3	Qiu-Han Yao, Wei-Yu Yang. Extending the evidence on ustekinumab safety in Crohn’s disease: A pharmacovigilance disproportionality analysis of FAERS data. World Journal of Gastroenterology 2026; 32(29): 120684 doi: 10.3748/wjg.120684 Abstract(80) \| Core Tip(55) \| Full Article(HTML)(366) \| Full Article (PDF)-558K(158) \| Full Article with Cover (PDF)-804K(52) \| Full Article (XML)-168K(23) \| Audio-995K(3) \| Peer-Review Report-315K(26) \| Answering Reviewers-622K(27) \| Times Cited (0) \| Total Visits (688) \| Open
4	Davide Giuseppe Ribaldone, Elisa Tribocco, Franco Scaldaferri, Marco Murgiano, Simone Parello, Federica Di Vincenzo, Angelo Del Gaudio, Pierluigi Puca, Daniele Napolitano, Alfredo Papa, Loris Riccardo Lopetuso, Lucrezia Laterza, Cristina Bezzio, Alessandro Armuzzi, Valeria Farinola, Edoardo Vincenzo Savarino, Fabiana Zingone, Brigida Barberio, Luisa Bertin, Alessia Todeschini, Angela Variola, Anna Maria Carvalhas Gabrielli, Francesca Ferretti, Rosanna Cannatelli, Antonietta Gerarda Gravina, Raffaele Pellegrino, Anna Viola, Clara De Francesco, Fabrizio Bossa, Luca Pastorelli, Carla Felice, Gabriele Dragoni, Daniele Canova, Linda Cingolani, Rocco Spagnuolo, Maria Maddalena Terpin, Alessandra Zilli, Ambra Magiotta, Francesco Segatta, Simone Saibeni, Ana Juverdeanu, Marta Vernero, Gian Paolo Caviglia. Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn’s Disease: The USBIOS–Italian Group for the Study of Inflammatory Bowel Disease Study. Clinical Gastroenterology and Hepatology 2026; doi: 10.1016/j.cgh.2026.08.014
5	Chuong Dinh Nguyen, Luan Minh Dang. Biosimilars in inflammatory bowel disease: Beyond evidence, toward trust and implementation. World Journal of Gastroenterology 2026; 32(28): 119462 doi: 10.3748/wjg.119462 Abstract(58) \| Core Tip(57) \| Full Article(HTML)(470) \| Full Article (PDF)-1084K(51) \| Full Article with Cover (PDF)-1358K(49) \| Full Article (XML)-199K(23) \| Audio-516K(3) \| Peer-Review Report-223K(25) \| Answering Reviewers-114K(27) \| Times Cited (0) \| Total Visits (694) \| Open
6	Shannon L. Piche, Michelle D. Becker, Shubha Bhat, Linda L. Huang, Sunanda V. Kane. Integration of Ustekinumab Biosimilars into Inflammatory Bowel Disease Care: Evidence, Implementation, and Patient-Centered Considerations. Advances in Therapy 2026; 43(7) doi: 10.1007/s12325-026-03584-6

Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.